What we’re seeing in the data, the policy environment, and the field.
Analysis written when the data has something worth saying. We publish based on substance rather than volume, for pharmaceutical commercial teams, policy audiences, and the public interest community.
Featured Article
ASCO 2026: New Data Highlight Advances in Prostate Cancer Treatments
New research presented at the 2026 ASCO Annual Meeting, held May 29 through June 2 in Chicago, showed that Nubeqa (darolutamide) was […]
Research Library
Long-form analysis built on the full census of Medicare claims.
Methodology included, so your team can check the work.
No posts found.
Latest Articles
Federal Regulators Hand Insurers a Win with Favorable 2027 MA Rate Hike
Despite concerns over program integrity and overspending, CMS approved a significantly larger 2027 Medicare Advantage (MA) pay raise than initially proposed, following […]
Medicare FFS Improper Payments Top $28B, Fueled by Documentation Gaps, SNFs
Despite years of progress in lowering error rates, traditional Medicare still made more than $28.8 billion in improper payments in the 2025 […]
It’s time for tech and biotech to unite — here’s why
Customers always look for ways to make life better. Use this expression as an alternative to the common phrase “new and improved.”
5 questions every biotech CISO should ask software providers
If you’re the one responsible for keeping track of company meetings, here's everything you need to know about writing effective work ad.